Chiron suffers exchange rate dampener in first quarter
This article was originally published in Clinica
Excluding the effect of foreign currency changes, Chiron's product sales would have risen 9% in the first quarter, above the actual 5% increase to $251 million. The diagnostics turnover of the US biotechnology company was up a strong 10%, supported by sales of bDNA probe tests which more than doubled to $13 million compared with $6 million in the previous year.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.